This Research Topic in Frontiers in Immunology aims to enhance our understanding of the impact of microbes on cancer biology. The interaction between microbes and cancer represents a rapidly growing field with significant implications for diagnosis and treatment.
Microbial infections, such as HPV and H. pylori, directly contribute to certain cancers by inducing mutations and inflammation. Dysbiosis in the gut, vaginal, and skin microbiomes has been associated with colorectal, cervical, and skin cancers, respectively. The composition of the tumor microbiome influences cancer development and response to therapy, with some microbes promoting tumorigenesis and others exhibiting anti-tumor effects. Microbial engineering facilitates precise cancer diagnosis through engineered bacteria, detecting biomarkers and delivering targeted therapy, offering the promise of early detection and personalized treatment. Moreover, harnessing microbial metabolites, such as antibiotics and immunomodulators, presents a multifaceted approach to cancer therapy, disrupting tumor growth and enhancing immune responses while minimizing drug resistance and toxicity.
Considering the significant impact of microbial influences on cancer progression and prevention, we invite contributions from researchers across disciplines to explore the latest discoveries, methodologies, and clinical implications related to microbes or microbial products.
Some potential questions for exploration include:
• How do microbial infections affect cancer development?
• How does the crosstalk between the microbiota and host factors influence cancer progression and treatment?
• In what ways does microbial engineering contribute to the development of cancer diagnosis and treatment?
• Can probiotics effectively prevent cancer progression?
• How can engineered microbes be tailored to develop new diagnostics and therapeutics?
• What opportunities exist for exploiting microbial products/metabolites for cancer-related clinical applications?
• How does the tumor microbiome influence cancer development?
Through collaborative efforts, we aim to deepen our understanding of microbial influences on human health and pave the way for innovative approaches in patient care and disease management.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic."
This Research Topic in Frontiers in Immunology aims to enhance our understanding of the impact of microbes on cancer biology. The interaction between microbes and cancer represents a rapidly growing field with significant implications for diagnosis and treatment.
Microbial infections, such as HPV and H. pylori, directly contribute to certain cancers by inducing mutations and inflammation. Dysbiosis in the gut, vaginal, and skin microbiomes has been associated with colorectal, cervical, and skin cancers, respectively. The composition of the tumor microbiome influences cancer development and response to therapy, with some microbes promoting tumorigenesis and others exhibiting anti-tumor effects. Microbial engineering facilitates precise cancer diagnosis through engineered bacteria, detecting biomarkers and delivering targeted therapy, offering the promise of early detection and personalized treatment. Moreover, harnessing microbial metabolites, such as antibiotics and immunomodulators, presents a multifaceted approach to cancer therapy, disrupting tumor growth and enhancing immune responses while minimizing drug resistance and toxicity.
Considering the significant impact of microbial influences on cancer progression and prevention, we invite contributions from researchers across disciplines to explore the latest discoveries, methodologies, and clinical implications related to microbes or microbial products.
Some potential questions for exploration include:
• How do microbial infections affect cancer development?
• How does the crosstalk between the microbiota and host factors influence cancer progression and treatment?
• In what ways does microbial engineering contribute to the development of cancer diagnosis and treatment?
• Can probiotics effectively prevent cancer progression?
• How can engineered microbes be tailored to develop new diagnostics and therapeutics?
• What opportunities exist for exploiting microbial products/metabolites for cancer-related clinical applications?
• How does the tumor microbiome influence cancer development?
Through collaborative efforts, we aim to deepen our understanding of microbial influences on human health and pave the way for innovative approaches in patient care and disease management.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic."